48 or 370 to 1000 and More

TL;DR

This paper discusses how the IMCA-CAT facility uses synchrotron-based research to speed up drug discovery through macromolecular crystallography.

Contribution

The paper highlights the role of the IMCA-CAT in advancing ultra-high throughput crystallography for drug development.

Findings

The IMCA-CAT has focused on accelerating drug discovery through structural biology for over 25 years.

New technologies have enabled expansion and increased throughput in macromolecular crystallography.

There is a growing need for faster drug development, driving innovation in crystallography.

Abstract

Structure is of vital importance to structure-based drug design, significantly impacting both target selection and the rate of drug development. Increasing numbers of drug development portfolios, growing numbers of pharmaceutical and biotech companies, and demands for faster development are key drivers for technology development in macromolecular crystallography. For more than 25 years, the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA-CAT) has focused exclusively on accelerating drug discovery and development through synchrotron-based structural biology research. Ultra- high throughput is an important goal of the facility. In pursuing this goal, the leveraging of new technologies has driven further technology development, enabling expansion and pushing limits.